All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Lupin receives FDA approval for Armlupeg (pegfilgrastim-unne) biosimilar targeting febrile neutropenia in cancer patients
Protein therapy, cancer, biosimilar, pegfilgrastim, neutropenia, chemotherapy supportive care - Read more

Johnson & Johnson receives European Commission approval for IMAAVY (nipocalimab) FcRn blocker treating generalised myasthenia gravis
Monoclonal antibody, autoimmune, FcRn blocker, generalized myasthenia gravis, IgG reduction - Read more

THE GOOD
Business Development & Partnerships

Akebia, Q32 Bio partnership on rare kidney disease complement inhibitor ADX-097, $12M guaranteed plus $580M milestones
Licensing deal, rare disease, complement inhibitor, milestone payments - Read more

Microsize, Schedio acquire Lonza's Swiss micronization plant to expand European particle engineering capabilities
Acquisition, manufacturing, micronization technology, CDMO services - Read more

Regeneron, Tessera Therapeutics partner on gene editor for alpha-1 antitrypsin deficiency, $275M total deal value
Co-development, rare disease, gene therapy, milestone payments, equity investment - Read more

CCRM, IonQ collaborate on quantum computing applications for advanced therapies development with initial investment
Strategic collaboration, advanced therapies, quantum computing, AI/ML, drug discovery, equity investment - Read more

Perseus Proteomics, Eurus Therapeutics form joint research agreement combining antibody library with genome editing technology
Research collaboration, antibody, drug discovery, genome editing - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Belite Bio's tinlarebant hits Ph3 primary endpoint for Stargardt disease, setting up potential first approval
Small molecule, ophthalmology, Stargardt disease, retinal degeneration, visual receptor antagonist - Read more

Generate:Biomedicines advances AI-designed GB-0895 TSLP antibody to Ph3 trials for severe asthma treatment
Antibody, autoimmune, monoclonal antibody, severe asthma, TSLP target, AI-designed - Read more

AbbVie advances Aquipta (atogepant) CGRP receptor blocker toward EU label expansion after positive Ph3 acute migraine results
Small molecule, neurological, CGRP receptor antagonist, migraine, acute treatment - Read more

HighTide's HTD1801 achieves superior HbA1c reduction versus dapagliflozin in Ph3 type 2 diabetes mellitus trial
Small molecule, metabolic, type 2 diabetes, HbA1c reduction, cardiometabolic - Read more

THE GOOD
Fundraises

European Investment Bank, Angelini partner to invest €150M ($174M) in European health startups over six years
Equity investment, biotech, digital health, medtech - Read more

Protego raises $130M Series B, light chain amyloidosis small-molecule drug development
Rare disease, small molecule, protein folding, clinical-stage - Read more

Morphocell Technologies raises $50M Series A for tissue therapeutics organ replacement
Tissue therapeutics, liver disease, regenerative medicine, preclinical - Read more

Edison Oncology raises $25M IPO, Phase 2 targeted small-molecule oncology therapies
Oncology, small molecule, clinical-stage, targeted therapy - Read more

Belite Bio raises $350M public offering, retinal disease therapeutics commercialization preparation
Clinical-stage, degenerative retinal diseases, ophthalmology, rare disease - Read more

Juniper Biosciences raises $40M Seed, developing innovative radiopharmaceutical pipeline
Radiopharmaceuticals, oncology, imaging and therapy, clinical-stage - Read more

THE GOOD
Marketing

Tanabe Pharma drops Mitsubishi name following $3.3B Bain Capital takeover, rebrands globally
Strategic, major transaction, operational, financial - Read more

THE GOOD
Mergers & Acquisitions

Orphalan acquires Orphelia Pharma to expand rare pediatric neurology and oncology drug capabilities
Orphan drugs, rare disease, strategic, major transaction - Read more

THE GOOD
Politics & Policy

UK agrees to pay 25% more for new drugs, thus exempting British pharmas from US tariffs
Pricing, strategic, financial, major transaction - Read more

THE GOOD
Product Launches

Sandoz launches first denosumab biosimilars in Europe for cancer bone disease and osteoporosis treatment
Monoclonal antibody, oncology, strategic, major transaction - Read more

Samsung Bioepis launches denosumab biosimilars OBODENCE and XBRYK in Europe starting December 2025
Monoclonal antibody biosimilar, bone disorders, competitive, market access - Read more

THE GOOD
Regulatory

FDA launches agentic AI program for staff to assist with reviews, inspections, and surveillance tasks
Regulatory, operational, strategic, artificial intelligence - Read more

THE GOOD
Strategic Plans

Eli Lilly cuts Zepbound prices again on direct platform, responding to Novo Nordisk's $199 monthly pricing
GLP-1 receptor agonist, obesity, competitive, cost reduction - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
No Bad New Today!

(first time this has happened!)

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here